Rigel licenses olutasidenib to Kissei for Japan, Korea, Taiwan; $10M upfront + up to $152.5M milestones

RIGEL PHARMACEUTICALS INC

Rigel receives $10M upfront; eligible for up to $152.5M in development, regulatory, and commercial milestones.
Mid-twenties to low-thirties percent tiered royalty on net sales; Kissei funds all development in territory.
Forma Therapeutics (Novo Nordisk) owed $2.3M from the upfront payment under prior sublicense.
Rigel retains global rights outside Japan, Korea, Taiwan; supplies bulk drug product under separate agreement.
Kissei responsible for companion diagnostic costs in Japan; Rigel shares 50% up to $3M, creditable against milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.